BARER SOL J 4

What happened

Sol J. Barer, a director of Teva Pharmaceutical Industries Ltd. (TEVA), received a grant of 10,863 restricted share units (RSUs) on May 28, 2026. The award is reported as a derivative grant (code A) with $0 cash paid at grant; the economic value depends on TEVA’s share price when/if the RSUs settle. The RSUs vest on May 28, 2027.

Key details

• Transaction date: May 28, 2026 (reported on Form 4 filed June 1, 2026).
• Security: 10,863 restricted share units (derivative award); reported acquisition price $0.00.
• Vesting: RSUs vest on May 28, 2027 (Footnote F2).
• Settlement: Each RSU represents the contingent right to receive one ordinary share or, at the compensation committee’s option, the cash value of one ordinary share (Footnote F1).
• ADS note: Ordinary shares may be represented by American Depositary Shares (ADS), currently 1 ADS = 1 Ordinary Share (Footnote F3).
• Shares owned after the transaction: not specified in the excerpt of the filing.
• Timeliness: Form 4 was filed June 1, 2026 — four days after the grant date. Form 4s are normally due within two business days of the transaction, so this filing appears to have been submitted after the typical deadline.

Context

This was an award of RSUs (compensation), not an open-market purchase or sale. Such grants are common for directors and tie future pay to company stock performance; they do not indicate immediate buying or selling pressure. The ultimate value to the insider will depend on Teva’s share price at settlement and whether the committee elects cash or shares.